Tharimmune and Intract Pharma to Merge and Form Transformative Oral Biologics Company

Tharimmune, Inc. and Intract Pharma Ltd. have announced their entry into a nonbinding letter of intent to merge. This merger aims to create a leading company in the field of oral biologics.

The combined entity will take advantage of synergies between Tharimmune's clinical-stage assets and Intract's delivery platform. The transaction is expected to close in the first quarter of 2025. Post-merger, Intract's shareholders will own 49% of the new Tharimmune, Inc., and the company will trade under the ticker "THAR" on Nasdaq.

Tharimmune foresees multiple milestones over the next 24 months, driven by a strong clinical pipeline and experienced management. The merger aligns with their strategy to expand their product pipeline and enhance their standing in the biologics market, which is valued in the billions of dollars.

The merger holds promise for improving patient compliance and outcomes through innovative delivery methods for biologics. By making treatments less invasive, the companies aim to bolster patient adherence and quality of life.